Zura Bio (NASDAQ:ZURA) Releases Quarterly Earnings Results, Misses Expectations By $0.31 EPS

Zura Bio (NASDAQ:ZURA) announced its quarterly earnings data on Thursday. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.31), Zacks reports.

Zura Bio Trading Down 10.1%

NASDAQ:ZURA traded down $0.62 during trading hours on Friday, hitting $5.50. 1,203,910 shares of the company traded hands, compared to its average volume of 600,656. Zura Bio has a twelve month low of $0.97 and a twelve month high of $7.44. The firm has a 50-day moving average of $6.17 and a 200 day moving average of $4.53. The stock has a market capitalization of $357.63 million, a price-to-earnings ratio of -5.19 and a beta of 0.18.

Analyst Ratings Changes

Several research firms have commented on ZURA. Wedbush began coverage on shares of Zura Bio in a research report on Monday, February 9th. They set an “outperform” rating and a $15.00 target price on the stock. Leerink Partners upgraded Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Friday, January 9th. Finally, Oppenheimer reduced their target price on Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.40.

Insider Activity at Zura Bio

In other news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were bought at an average price of $6.25 per share, with a total value of $12,500,000.00. Following the acquisition, the insider owned 6,552,725 shares of the company’s stock, valued at $40,954,531.25. This trade represents a 43.93% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 14.23% of the company’s stock.

Institutional Trading of Zura Bio

Several institutional investors have recently bought and sold shares of ZURA. Allworth Financial LP bought a new stake in shares of Zura Bio during the fourth quarter valued at approximately $30,000. Savant Capital LLC lifted its holdings in Zura Bio by 190.4% during the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after buying an additional 21,249 shares in the last quarter. Scientech Research LLC bought a new position in Zura Bio in the 3rd quarter valued at $45,000. AQR Capital Management LLC bought a new position in Zura Bio in the 1st quarter valued at $72,000. Finally, Forefront Wealth Partners LLC acquired a new stake in shares of Zura Bio in the 3rd quarter valued at $93,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.